The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Kadmon Oceania Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
3 result(s) found, displaying 1 to 3
-
Australian Public Assessment Report (AusPAR)New AusPAR for Rholistiq (belumosudil) for the treatment of patients with chronic graft-versus-host disease aged 12 years and older.
-
Prescription medicine decision summaryTGA decision: Rholistiq (belumosudil mesilate) is approved to treat chronic graft-versus-host disease (GVHD)
-
Prescription medicine registrationActive ingredients: belumosudil mesilate.